Skip to Content

Join the 'Seebri Neohaler' group to help and get support from people like you.

Seebri Neohaler News

Sunovion Receives FDA Approval for Lonhala Magnair (glycopyrrolate) Inhalation Solution to Treat COPD

Posted 8 Dec 2017 by Drugs.com

MARLBOROUGH, Mass.--(BUSINESS WIRE) December 5, 2017 --Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for Lonhala Magnair (glycopyrrolate) Inhalation Solution (25 mcg twice daily), also known as SUN-101/eFlow®, for the long-term, maintenance treatment of airflow obstruction in people with chronic ...

FDA Approves Seebri Neohaler (glycopyrrolate) for COPD

Posted 4 Nov 2015 by Drugs.com

EAST HANOVER, N.J., Oct. 29, 2015 Novartis announced today that the US Food and Drug Administration (FDA) has approved Seebri Neohaler (glycopyrrolate) inhalation powder 15.6 mcg as a stand-alone monotherapy for COPD. Novartis expects that Seebri Neohaler will be available in the first quarter of 2016. Seebri is delivered via the low resistance Neohaler inhaler, which makes it suitable for ...

Ask a Question

Further Information

Related Condition Support Groups

Chronic Obstructive Pulmonary Disease, Maintenance

Seebri Neohaler Patient Information at Drugs.com